Open Access Open Access  Restricted Access Subscription Access

Understanding the Effectiveness of Drugs in Neutropenia Management

Muralinath E ., Sony Sharlet E., Sravani Pragna K., Kalyan C., Vinayasree . C, Guru Prasad M., Venkat Naveen A., Sravani ., Archana Jain

Abstract


Neutropenia is manifested by an abnormally low number of neutrophils. Neutropenis can occur due to many causes such as chemotherapy, radiation therapy and certain medications. A very few drugs namely filgastim and pegfilgadtim can increase neutrophils. Granulocyte colony_ stimulating factors (G _ CSF s) ate a class of cytokines that play a main role in enhancing neutrophils. An administration of G_CSF plays a role in cancer patients undergoing chemotherapy to treat neutropenia. Common side effects of G _ CSF therapy are bone pain, fever and headache. G _ CSF s should be used with caution in patients with certain medical situations namely leukemia, as they can increase the growth of cancer cells. A very few myeloid growth factors such as sargramostim may be considered in treating neutropenic patients. In some cases, treating the underlying cause of neutropenia is the most effective approach. It is finally concluded that effective management of neutropenia is related to the variety of drugs tailored to the underlying cause and severity of the condition.

 


Full Text:

PDF

References


Vaillant, A. A. J., & Qurie, A. (2022). Immunodeficiency. In StatPearls [Internet]. StatPearls Publishing.

Rezaei, N., Moazzami, K., Aghamohammadi, A., & Klein, C. (2009). Neutropenia and primary immunodeficiency diseases. International Reviews of Immunology, 28(5), 335-366.

Bohn, G., Welte, K., & Klein, C. (2007). Severe congenital neutropenia: new genes explain an old disease. Current opinion in rheumatology, 19(6), 644-650.

Nargund, A. R., Madhumathi, D. S., Premalatha, C. S., Rao, C. R., Appaji, L., & Lakshmidevi, V. (2010). Accelerated phase of chediak higashi syndrome mimicking lymphoma—a case report. Journal of pediatric hematology/oncology, 32(6), e223-e226.

Hsieh, M. M., Everhart, J. E., Byrd-Holt, D. D., Tisdale, J. F., & Rodgers, G. P. (2007). Prevalence of neutropenia in the US population: age, sex, smoking status, and ethnic differences. Annals of internal medicine, 146(7), 486-492.

Weycker, D., Barron, R., Kartashov, A., Legg, J., & Lyman, G. H. (2014). Incidence, treatment, and consequences of chemotherapy-induced febrile neutropenia in the inpatient and outpatient settings. Journal of Oncology Pharmacy Practice, 20(3), 190-198.

Jolis, L., Carabantes, F., Pernas, S., Cantos, B., López, A., Torres, P., ... & PRAXIS Study Group. (2013). Incidence of chemotherapy‐induced neutropenia and current practice of prophylaxis with granulocyte colony‐stimulating factors in cancer patients in S pain: a prospective, observational study. European Journal of Cancer Care, 22(4), 513-521.

Rider, N. L., Jameson, M. B., & Creech, C. B. (2018). Chronic granulomatous disease: epidemiology, pathophysiology, and genetic basis of disease. Journal of the Pediatric Infectious Diseases Society, 7(suppl_1), S2-S5.

Möttönen, M., Lanning, M., Baumann, P., & Saarinen‐Pihkala, U. M. (2003). Chediak‐Higashi syndrome: four cases from Northern Finland. Acta Paediatrica, 92(9), 1047-1051.

Khoo, A. L., Zhao, Y. J., Teng, M., Ying, D., Jin, J., Chee, Y. L., ... & Chai, L. Y. A. (2018). Evaluation of a risk-guided strategy for empirical carbapenem use in febrile neutropenia. International journal of antimicrobial agents, 52(3), 350-357.


Refbacks

  • There are currently no refbacks.